Targeting fibroblast TXNDC5 resolves tumor desmoplasia and PD-1 resistance in colorectal cancer with mesenchymal traits
Kai-Lin Cheng, Chih-I Chen, Shu-Han Yu, Huai-Wen Liang, Yi-Wei Tsai, Chen-Ting Hung, Yu-Shan Lin, Gang-Hui Lee, Po-Yu Chen, Ming-Jer Tang, Yueh-Feng Wu, Sung-Jan Lin, Jen-Kuang Lee, Linda Chia-Hui Yu, Shuei-Liong Lin, Shih-Yu Chen, Wen-Chih Lee, Yung-Ming Jeng, Ruby Yun-Ju Huang, Ruey-Hwa Chen, Chin · 2026
Read Targeting fibroblast TXNDC5 resolves tumor desmoplasia and PD-1 resistance in colorectal cancer with mesenchymal traits by Kai-Lin Cheng, Chih-I Chen, Shu-Han Yu, Huai-Wen Liang, Yi-Wei Tsai, Chen-Ting Hung, Yu-Shan Lin, Gang-Hui Lee, Po-Yu Chen, Ming-Jer Tang, Yueh-Feng Wu, Sung-Jan Lin, Jen-Kuang Lee, Linda Chia-Hui Yu, Shuei-Liong Lin, Shih-Yu Chen, Wen-Chih Lee, Yung-Ming Jeng, Ruby Yun-Ju Huang, Ruey-Hwa Chen, Chin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13396657.txt.
Description
Cheng and team target, in 2026, a fibroblast protein called TXNDC5 that builds the stiff shield protecting mesenchymal colorectal cancers from immunotherapy. TXNDC5, a protein disulfide isomerase, runs high in cancer-associated fibroblasts in human and mouse tumors. It props up the TGF-beta receptor TGFBR1, boosting the signaling that activates fibroblasts and lays down the stiff, immune-excluding matrix around these tumors.
Deleting Txndc5 only in fibroblasts softened tumors, opened their blood vessels, and reduced oxygen starvation inside them in mice. The remodeling curbed pro-tumor inflammatory fibroblast types and let cytotoxic T cells infiltrate, restraining tumor growth. Most importantly, softening the stroma made the tumors respond to PD-1 blockade, the immunotherapy they normally resist. Patient data underline the stakes: in one cohort, high TXNDC5 tumors carried worse survival than low ones, with 80 patients per group. The authors propose TXNDC5 as a stromal drug target.
Catalog record
| CREATOR | Kai-Lin Cheng, Chih-I Chen, Shu-Han Yu, Huai-Wen Liang, Yi-Wei Tsai, Chen-Ting Hung, Yu-Shan Lin, Gang-Hui Lee, Po-Yu Chen, Ming-Jer Tang, Yueh-Feng Wu, Sung-Jan Lin, Jen-Kuang Lee, Linda Chia-Hui Yu, Shuei-Liong Lin, Shih-Yu Chen, Wen-Chih Lee, Yung-Ming Jeng, Ruby Yun-Ju Huang, Ruey-Hwa Chen, Chin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 103 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |